8-K: Tvardi's IPF Drug Fails Phase 2 Trial Goals

Tvardi Therapeutics announced that its Phase 2 REVERT trial for TTI-101 in idiopathic pulmonary fibrosis did not meet its primary goals.

Summary

• Tvardi Therapeutics' Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals.
• The randomized, double-blind, placebo-controlled study assessed safety, pharmacokinetics, and exploratory lung function outcomes.
• 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29), or placebo (n=29), with 58% receiving concomitant nintedanib.
• Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms.
• Forced Vital Capacity (FVC) change from baseline to 12 weeks was -22.2 mL for placebo, -61.1 mL for 400mg, and -102.8 mL for 800mg.
• The proportion of patients demonstrating FVC improvement from baseline was 41% for placebo, 39% for 400mg, and 44% for 800mg.
• The placebo-treated patients' FVC decline was lower than expected compared to historical controls, complicating interpretation.

Sentiment

Score: 3

Explanation: The failure of the Phase 2 REVERT trial for TTI-101 in IPF is a major negative event, indicating a significant setback for a key pipeline asset. However, the company maintains a cash runway into Q4 2026 and has ongoing trials for TTI-101 in hepatocellular carcinoma and a next-generation STAT3 inhibitor, TTI-109, which provide some future prospects.

Positives

• The company maintains $41.0 million in cash, cash equivalents, and short-term investments as of June 30, 2025, expected to fund operations into the fourth quarter of 2026.
• Tvardi remains on track to report preliminary topline data in the first half of 2026 from a healthy volunteer study on its next-generation STAT3 inhibitor, TTI-109.
• Preliminary topline data is also expected in the first half of 2026 from the Phase 2 trial of TTI-101 in hepatocellular carcinoma.
• TTI-109 is designed to enhance STAT3 targeting with potential for improved tolerability and expansion into other STAT3-driven indications.

Negatives

• The Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals, showing no statistically significant differences between placebo and treatment arms.
• High discontinuation rates were observed in the TTI-101 treatment arms (56.7% for 400mg and 62.1% for 800mg) compared to the placebo group (10.3%).
• Discontinuation rates in the TTI-101 population were primarily driven by gastrointestinal adverse events, with higher rates among patients on concurrent nintedanib.
• The preliminary data showed a dose-dependent decline in FVC for TTI-101 treated arms (-61.1 mL for 400mg, -102.8 mL for 800mg) compared to placebo (-22.2 mL).
• The unexpected performance of the placebo arm, with a lower-than-expected FVC decline, made definitive conclusions difficult.

Risks

• Uncertainties associated with Tvardi's product candidates and the clinical development and regulatory approval process, including potential delays in clinical trial completion.
• Significant net losses incurred since inception.
• Ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance product candidates through clinical development.
• Timing of the availability of data from clinical trials.
• Outcome of preclinical testing and clinical trials, including the ability to satisfy governmental or regulatory requirements.
• Requirement for additional capital to continue advancing product candidates, which may not be available on favorable terms or at all.
• Ability to attract, hire, and retain skilled executive officers and employees.
• Ability to protect intellectual property and proprietary technologies.
• Reliance on third parties, contract manufacturers, and contract research organizations.
• Adverse effects from other economic, business, or competitive factors.
• Risks associated with changes in applicable laws or regulations.

Future Outlook

The company will conduct additional analyses to further understand the REVERT trial results and inform next steps for TTI-101 in IPF. Tvardi remains on track to report preliminary topline data in the first half of 2026 from a healthy volunteer study on its next-generation STAT3 inhibitor, TTI-109, and from the Phase 2 trial of TTI-101 in hepatocellular carcinoma. TTI-109 is designed for enhanced STAT3 targeting and improved tolerability, with potential for expansion into other STAT3-driven indications after the healthy volunteer study.

Management Comments

• "In the aggregate, we did not observe a benefit of TTI-101 treatment in this IPF study."
• "The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time."
• "We are conducting additional analyses to further understand the results and inform our next steps."
• "Importantly, we remain on track to report preliminary topline data in the first half of 2026 from a healthy volunteer study on our next-generation STAT3 inhibitor, TTI-109, and from the Phase 2 trial of TTI-101 in hepatocellular carcinoma."

Industry Context

The failure of Tvardi's TTI-101 in the Phase 2 REVERT trial for Idiopathic Pulmonary Fibrosis (IPF) highlights the significant challenges in developing effective treatments for this progressive and fatal lung disease. IPF is a complex condition with limited therapeutic options, primarily nintedanib and pirfenidone, which slow disease progression but do not cure it. The unexpected performance of the placebo arm, showing a lower-than-expected decline in FVC, further complicates clinical trial design and interpretation in this area. While STAT3 inhibition represents a novel mechanistic approach to fibrosis-driven diseases, this setback underscores the high-risk nature of drug development in severe indications. The company's continued focus on TTI-101 in hepatocellular carcinoma and the development of TTI-109 suggests a strategic pivot or diversification of risk following this clinical disappointment.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or detailed results for direct comparison to industry benchmarks.
• The company noted that the placebo-treated patients' FVC decline was lower than expected compared to historical controls, indicating an unusual outcome within the context of IPF clinical trials, but no specific historical control data or studies were detailed.

Stakeholder Impact

• Shareholders: Likely to experience a negative impact on share price due to the failure of a significant clinical trial, leading to reduced confidence in the TTI-101 program for IPF.
• Patients with IPF: Disappointment as a potential new treatment option has failed to demonstrate efficacy, leaving limited therapeutic alternatives.
• Employees: Potential for shifts in R&D focus and resource allocation, though the company's other programs offer continued work.
• Investment Professionals: Will re-evaluate the company's pipeline and valuation, focusing more on the TTI-101 HCC program and TTI-109 development.

Next Steps

• Conduct additional analyses to further understand the results of the REVERT trial and inform next steps for TTI-101 in IPF.
• Report preliminary topline data in the first half of 2026 from a healthy volunteer study on the next-generation STAT3 inhibitor, TTI-109.
• Report preliminary topline data in the first half of 2026 from the Phase 2 trial of TTI-101 in hepatocellular carcinoma.
• Assess the opportunity to expand TTI-109 into other STAT3-driven indications once the healthy volunteer study is completed.

Key Dates

Recommendation

The failure of a Phase 2 clinical trial for a lead candidate in a significant indication like Idiopathic Pulmonary Fibrosis represents a substantial negative event for a clinical-stage biopharmaceutical company. This outcome significantly diminishes the near-term value proposition of TTI-101 for IPF and introduces considerable uncertainty regarding the company's ability to bring this specific asset to market. While Tvardi has other pipeline assets (TTI-101 in HCC and TTI-109), the immediate impact of this failure warrants a "sell" recommendation for investors to mitigate potential downside risk associated with the primary clinical setback. The high discontinuation rates and lack of efficacy signal are concerning, despite the unexpected placebo performance.

Keywords

Tvardi Therapeutics, TVRD, Idiopathic Pulmonary Fibrosis, IPF, TTI-101, Phase 2 trial, REVERT trial, STAT3 inhibitor, biopharmaceutical, clinical trial results, drug development, hepatocellular carcinoma, TTI-109, pulmonary fibrosis, clinical-stage, biotech